Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Ossenkoppele

Showing results (151-160 of 152) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 152 results.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 16

Showing results (151-160 of 152) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 152 results.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Pageof 16